2-Acetylamino-4-methyl-pentanoic acid [1-(1-formyl-butylcarbamoyl)-3-methyl-butyl]-amide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Acetylamino-4-methyl-pentanoic acid [1-(1-formyl-butylcarbamoyl)-3-methyl-butyl]-amide
• 英文别名: (2S)-2-acetamido-4-methyl-N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxopentan-2-yl]amino]pentan-2-yl]pentanamide
• 化学式: C₁₉H₃₅N₃O₄
• 分子量: 369.5
• InChiKey: MAPYTFXBSNSYKM-ULQDDVLXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Regulation of transgene expression following AAV transduction
  申请人：——

  公开号：US20030003583A1

  公开（公告）日：2003-01-02

  The present invention provides for methods for regulating gene expression both in vitro and in vivo. Specifically, the present invention provides for methods of using adeno-associated virus for transduction of a target gene in a variety of tissues wherein the expression of the transgene is regulated by administration of a proteasome inhibitor. As an example, a therapeutic gene can be delivered in vivo by an adeno-associated virus to a tissue that is not normally transduced by adeno-associated virus. The host would then be administered a proteasome inhibitor in order to induce expression of the therapeutic gene. Hence, the proteasome inhibitor would be administered only when gene expression is desired.

  本发明提供了调节体外和体内基因表达的方法。具体地说，本发明提供了使用腺相关病毒在各种组织中转导目的基因的方法，其中转基因的表达是通过服用蛋白酶体抑制剂来调节的。举例来说，治疗基因可以通过腺相关病毒在体内传递到通常不被腺相关病毒转导的组织中。然后给宿主注射蛋白酶体抑制剂，以诱导治疗基因的表达。因此，蛋白酶体抑制剂只有在需要表达基因时才会施用。
• [EN] REGULATION OF TRANSGENE EXPRESSION FOLLOWING AAV TRANSDUCTION<br/>[FR] REGULATION DE L'EXPRESSION TRANSGENIQUE SUIVANT UNE TRANSDUCTION PAR AAV
  申请人：——

  公开号：WO2002101012A9

  公开（公告）日：2003-12-18

  [EN] The present invention provides for methods regulating gene expression both in vitro and in vivo. Specifically, the present invention provides for methods of using adeno-associated virus for transduction of a target gene in a variety of tissues wherein the expression of the transgene is regulated by administration of a proteasome inhibitor. As an example, a therapeutic gene can be delivered in vivo by an adeno-associated virus to a tissue that is not normally transduced by adeno-associated virus. The host would then be administered a proteasome inhibitor in order to induce expression of the therapeutic gene. Hence, the proteasome inhibitor would be administered only when gene expression is desired.
  [FR] L'invention concerne des procédés permettant de réguler l'expression génique à la fois in vitro et in vivo. L'invention concerne en particulier des procédés d'utilisation de virus associés aux adénovirus dans la transduction d'un gène cible dans divers tissus, l'expression de ce transgène étant régulée par l'administration d'un inhibiteur de protéasome. A titre d'exemple, un gène thérapeutique peut être administré in vivo par un virus associé aux adénovirus à un tissu qui n'est normalement pas transduit par un virus associé aux adénovirus. L'hôte est ensuite administré à un inhibiteur de protéasome, de sorte à induire l'expression du gène thérapeutique. L'inhibiteur de protéasome n'est par conséquent administré que lorsque l'expression génique est désirée.